GleamWall
中文EN

ORKA Oruka Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 907654 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-18.1%
ROA-17.5%
ROIC (approx.)-20.6%
Asset turnover—

Leverage & solvency

Liabilities / assets2.8%
Debt / equity0.00x
Current ratio29.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20232023-12-31
Income statement
Revenue—$0
R&D expense$100.64M$1.01M
SG&A expense$21.41M$6.28M
Operating income-$122.05M-$7.30M
Pretax income-$105.43M—
Income tax—$0
Net income-$105.43M-$5.34M
EBITDA-$121.97M-$7.28M
EPS (basic)—-0.37
EPS (diluted)—-0.37
Weighted avg. shares (diluted)—14.42M
Balance sheet
Cash & equivalents$46.94M$37.43M
Short-term investments$290.11M—
Current assets$343.86M$37.59M
PP&E, net$288,000$10,000
Total assets$488.62M$37.86M
Current liabilities$15.37M$637,000
Total liabilities$16.69M$841,000
Shareholders' equity$471.93M$37.02M
Shares outstanding48.72M14.50M
Cash flow statement
Operating cash flow-$88.21M-$5.01M
Capital expenditure$209,000$0
Free cash flow-$88.42M-$5.01M
Investing cash flow-$96.75M$0
Financing cash flow$170.31M$0
Depreciation & amortization$83,000$15,000
Stock-based compensation$24.24M$686,000

Free plan shows the latest 2 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.